Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2020 May 26;18(1):54.
doi: 10.1186/s12958-020-00610-2.

Effectiveness and safety of follitropin alfa (Ovaleap®) for ovarian stimulation using a GnRH antagonist protocol in real-world clinical practice: a multicenter, prospective, open, non-interventional assisted reproductive technology study

Peter Sydow  1 , Norbert Gmeinwieser  2 , Katrin Pribbernow  3 , Christoph Keck  4 , Inka Wiegratz  5
Affiliations
Observational Study

Effectiveness and safety of follitropin alfa (Ovaleap®) for ovarian stimulation using a GnRH antagonist protocol in real-world clinical practice: a multicenter, prospective, open, non-interventional assisted reproductive technology study

Peter Sydow et al. Reprod Biol Endocrinol. .

Abstract

Background: The use of recombinant human follicle-stimulating hormone (r-hFSH) in ovarian stimulation protocols for infertility treatment in assisted reproductive technology (ART) clinical practice is well established. More recent advancements include the availability of biosimilar r-hFSH products, which expand the choices available to healthcare practitioners and patients. Better understanding of how such a product contributes to routine clinical practice is valuable to help prescribers make informed treatment choices. The objective of this study was to examine the effectiveness and safety of ovarian stimulation (OS) with follitropin alfa (Ovaleap®) for routine IVF or intracytoplasmic sperm injection treatment in gonadotropin-releasing hormone (GnRH) antagonist cycles in real-world ART clinical practice.

Methods: This non-interventional, multicenter, prospective study was initiated in 34 specialized reproductive medicine centers in Germany. Eligible women were 18-40 years old with a body mass index < 30 kg/m2, menstrual cycle 24-35 days and anti-Müllerian hormone ≥1 ng/mL, who were undergoing a first OS cycle exclusively with Ovaleap® during routine ART using a GnRH antagonist protocol. Primary effectiveness outcomes were number of retrieved oocytes after OS and clinical pregnancy rate (CPR). Secondary outcomes included fertilization rate, number of transferred embryos, live birth delivery rate, safety, and user satisfaction with the Ovaleap® pen.

Result(s): Of 507 women screened, 463 received at least 1 dose of Ovaleap® and 439 had Visit 2 data (per protocol population; PPP). The mean(±SD) number of retrieved oocytes was 11.8 ± 7.2 (PPP). The CPR among women with documented embryo transfer was 41.3% (158/383), resulting in a live birth delivery rate of 31.6% (138/437) among PPP patients with available follow-up information. Overall, 8.6% (40/463) of women reported ≥1 adverse drug reaction. Ovarian hyperstimulation syndrome occurred in 23 (5.0%) patients, rated mild in 14 (3.0%), moderate in 8 (1.7%), and severe in 1 (0.2%). Patients reported high user satisfaction and high convenience with use of the Ovaleap® pen.

Conclusion: The effectiveness and safety of OS with Ovaleap® in a GnRH antagonist protocol were extended to real-world ART clinical practice for the first time.

Trial registration: Registered on 22 June 2016 (retrospectively registered) at ClinicalTrials.gov (NCT02809989).

Keywords: Biosimilar; Follitropin alfa; GnRH antagonist; Ovaleap; Recombinant human follicle-stimulating hormone; User satisfaction.

PubMed Disclaimer

Conflict of interest statement

PS: Received honoraria for consultancy, presentations, and involvement in clinical studies from Teva, Merck, and Ferring.

NG: Received personal fees from Pharmalog Institut für klinische Forschung GmbH, subcontracted service CRO of Teva GmbH Germany for this non-interventional study.

KP: Received honoraria for consultancy, presentations and involvement in clinical studies from Teva GmbH Germany/Pharmalog Institut für klinische Forschung GmbH.

CK: Received honoraria for consultancy and presentations from Teva GmbH Germany, Kade, Gedeon Richter, Exeltis, Merck Serono, Theramex.

IW: Received honoraria for consultancy, presentations, and involvement in clinical studies from Teva, Merck, Ferring, Theramex, MSD, Pharmalog.

Figures

Fig. 1
Fig. 1
Number of retrieved oocytes by age in patients in the per protocol population
See this image and copyright information in PMC

References

    1. Howles CM. Recombinant gonadotrophins in reproductive medicine: the gold standard of today. Reprod BioMed Online. 2006;12:11–13. doi: 10.1016/S1472-6483(10)60973-X. - DOI - PubMed
    1. Howles CM. Genetic engineering of human FSH (Gonal-F®) Hum Reprod Update. 1996;2:172–191. doi: 10.1093/humupd/2.2.172. - DOI - PubMed
    1. Harrison S, Wolf T, Abuzeid MI. Administration of recombinant follicle stimulating hormone in a woman with allergic reaction to menotropin: a case report. Gynecol Endocrinol. 2000;14:149–152. doi: 10.3109/09513590009167674. - DOI - PubMed
    1. van Wely M, Kwan I, Burt AL, Thomas J, Vail A, Van der Veen F, Al-Inany HG. Recombinant versus urinary gonadotrophin for ovarian stimulation in assisted reproductive technology cycles. Cochrane Database Syst Rev. 2011;2:cd005354. - PMC - PubMed
    1. European Medicines Agency. Ovaleap (follitropin alfa) [assessment report]. 31 July 2013. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_asses.... Accessed 31 Jan 2020.

Publication types

MeSH terms

Associated data